Top

Published in:

Open Access 01-12-2014 | Research article

Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

Authors: Zuli Yang, Yang Bai, Lijun Huo, Hao Chen, Jintuan Huang, Jizheng Li, Xinjuan Fan, Zihuan Yang, Lei Wang, Jianping Wang

Published in: BMC Cancer | Issue 1/2014

Abstract

Background

A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim of this study was to investigate the expression and function of ADAM8 in CRC.

Methods

Expression level of ADAM8 in CRC was evaluated by quantitative RT-PCR, western blot and immunohistochemical staining analysis. The role of ADAM8 in colorectal carcinogenesis was evaluated by in vitro assays. The correlations between ADAM8 status and clinicopathological features including survival were analyzed.

Results

ADAM8 was highly expressed in CRC tissues compared with adjacent normal tissues. Knockdown of ADAM8 in two CRC cell lines resulted in reduced cellular growth and proliferation, and increased apoptosis. Immunohistochemistry analysis showed no significant correlations of ADAM8 protein expression with clinicopathologic features. Survival analysis indicated that patients with ADAM8-positive tumors had worse 5-year overall survival (OS, p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors. Multivariate analysis indicated ADAM8 expression was an independent prognostic factor for both OS and DFS (both p< 0.001). Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p< 0.05). The 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05).

Conclusions

Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.

Available only for authorised users

Yang ZL, Wang JP, Wang L, Dong WG, Huang YH, Qin JZ, Zhan WH: Multivariate regression analysis of prognostic factors in colorectal cancer. Chin-Ger J Clin Oncol. 2003, 2 (3): 44-51.

Popat S, Hubner R, Houlston RS: Systematic review of micro-satellite instability and colorectal cancer prognosis. J Clin Oncol. 2005, 23: 609-618.CrossRefPubMed

Kelley RK, Wang G, Venook AP: Biomarker Use in Colorectal Cancer Therapy. J Natl Compr Canc Netw. 2011, 9 (11): 1293-1302.PubMedPubMedCentral

Yokota T: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?. Anticancer Agents Med Chem. 2012, 12 (2): 163-171.CrossRefPubMedPubMedCentral

Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010, 127 (2): 367-380.PubMed

Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW: Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD156): implications for neuronglia interactions during neurodegeneration. J Neurosci. 2000, 20: 7964-7971.PubMed

Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC: The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis. 2007, 25: 665-674.CrossRefPubMed

Dijkstra A, Postma DS, Noordhoek JA, Lodewijk ME, Kauffman HF, ten Hacken NH, Timens W: Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung. Virchows Arch. 2009, 454: 441-449.CrossRefPubMed

Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004, 10: 8363-8370.CrossRefPubMed

10.

Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med. 2007, 11 (5): 1162-1174.CrossRefPubMedPubMedCentral

11.

Roemer A, Schwettmann L, Jung M, Stephan C, Roigas J, Kristiansen G, Loening SA, Lichtinghagen R, Jung K: The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?. J Urol. 2004, 172: 2162-2166.CrossRefPubMed

12.

Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, Dietel M, Jung K, Kristiansen G: ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 2006, 449 (6): 628-636.CrossRefPubMed

13.

Zhang Y, Tan YF, Jiang C, Zhang K, Zha TZ, Zhang M: High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res. 2013, 19 (1): 79-88.CrossRefPubMed

14.

Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE: ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med. 2014, 6 (2): 278-294.PubMed

15.

Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, Blobel CP: ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl). 2010, 88 (5): 497-505.CrossRef

16.

Zhang W, Wan M, Ma L, Liu X, He J: Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer. Cell Biol Int. 2013, 37 (1): 47-53.CrossRefPubMed

17.

Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M, Higashiyama S: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2006, 312 (3): 331-339.PubMed

18.

Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze’ev A: Expression of L1-CAM and ADAM10 in human colon cancer cells induce metastasis. Cancer Res. 2007, 67 (16): 7703-7712.CrossRefPubMed

19.

Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 2011, 71 (3): 1071-1080.CrossRefPubMed

20.

Choi JS, Kim KH, Jeon YK, Kim SH, Jang SG, Ku JL, Park JG: Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Int J Cancer. 2009, 124 (6): 1258-1262.CrossRefPubMed

21.

Ashktorab H, Schäffer AA, Daremipouran M, Smoot DT, Lee E, Brim H: Distinct genetic alterations in colorectal cancer. PLoS One. 2010, 5 (1): e8879-CrossRefPubMedPubMedCentral

22.

Gillett CE, Springall RJ, Barnes DM, Hanby AM: Multiple tissue core arrays in histopathology research: avalidation study. J Pathol. 2000, 192: 549-553.CrossRefPubMed

23.

Xavier LL, Viola GG, Ferraz AC, Da Cunha C, Deonizio JM, Netto CA, Achaval M: A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Brain Res Protoc. 2005, 16 (1–3): 58-64.CrossRefPubMed

24.

Wu X, Zou Y, He X, Yuan R, Chen Y, Lan N, Lian L, Wang F, Fan X, Zeng Y, Ke J, Wu X, Lan P: Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol. 2013, 21 (2): 111-120.CrossRefPubMed

25.

Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher A: Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006, 65: 516-527.CrossRefPubMed

26.

Valkovskaya NV: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp Oncol. 2008, 30: 129-132.PubMed

27.

Hernández I, Moreno JL, Zandueta C, Montuenga L, Lecanda F: Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 2010, 29: 3758-3769.CrossRefPubMed

28.

Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D: ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer. 2012, 12: 76-CrossRefPubMedPubMedCentral

29.

Li Z, Liao Q, Wu Y, Liao M, Hao Y, Zhang S, Song S, Li B, Zhang YD: Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma. Pathol Oncol Res. 2012, 18: 657-661.CrossRefPubMed

30.

He S, Ding L, Cao Y, Li G, Deng J, Tu Y, Wang B: Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis. Med Oncol. 2012, 29: 2032-2037.CrossRefPubMed

31.

Li W, Ye F, Wang D, Sun X, Tong W, Lian G, Jiang J, Suo J, Zhang DY: Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer. 2013, 132 (8): 1851-1859.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/568/prepub

Title: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer
Authors: Zuli Yang
Yang Bai
Lijun Huo
Hao Chen
Jintuan Huang
Jizheng Li
Xinjuan Fan
Zihuan Yang
Lei Wang
Jianping Wang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-14-568

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice

Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA)

Detection of infectious organisms in archival prostate cancer tissues

Nutrition and lung cancer: a case control study in Iran

Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis

RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures

Keynote webinar | Spotlight on antibody–drug conjugates in cancer